AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36698168
Drug: Home-based tablet-based
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-based tablet-based BCI intervention
Trial: 36698168
Drug: Clinic-based tablet-based
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based tablet-based BCI intervention
Trial: 36698194
Drug: Tobacco cessation
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco cessation pharmacotherapy (varenicline) paired with behavioral support
Trial: 36698210
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation group therapy
Trial: 36698447
Drug: Cleansing gel
RxNorm normalized name: salicylic acid 0.7 % Cleansing Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and lipohydroxy acid 0.05%
Trial: 36700571
Drug: Home-based pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based pulmonary rehabilitation program with telecoaching (weekly phone calls from a physiotherapist)
Trial: 36700734
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809 25 mg once daily
Trial: 36700734
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and digoxin alone
Trial: 36701184
Drug: Over-the-counter pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter pain and indigestion medications
Trial: 36701184
Drug: Indigestion medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigestion medications
Trial: 36701531
Drug: Mindful yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful yoga intervention (MYI) as add-on to treatment as usual (TAU)
Trial: 36701613
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake ('fed') within 2 hours of the test
Trial: 36701651
Drug: OBI-999 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBI-999 at 1.2 mg/kg every 21 days
Trial: 36701651
Drug: OBI-999 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBI-999 at 1.6 mg/kg
Trial: 36701797
Drug: Optimized acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized acute treatment of migraine
Trial: 36702070
Drug: Neratinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib dose escalation over the first 2 weeks (DE1)
Trial: 36702070
Drug: Neratinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib dose escalation over the first 4 weeks (DE2)
Trial: 36702070
Drug: Loperamide (L)
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide (L)
Trial: 36702070
Drug: Neratinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib treatment
Trial: 36702138
Drug: G-CSF, decitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF, decitabine, and busulfan-cyclophosphamide conditioning
Trial: 36702329
Drug: Mivavotinib 60-120
RxNorm normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivavotinib 60-120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity
Trial: 36702934
Drug: Acyclovir administered
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir administered intravenously every 8 hours with a 1-hour infusion of 500 mg/m
Trial: 36703109
Drug: Tablet-based electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based electronic decision-support system (EDSS) used by healthcare providers during ANC visits.
Trial: 36703120
Drug: ADIVA (advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADIVA (advanced double intravenous vasopressor automated system)
Trial: 36703120
Drug: DIVA (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIVA (double intravenous vasopressor automated system)
Trial: 36703250
Drug: Immediate intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate intervention (8-session emotion and self-regulation group intervention with daily app-based prompts)
Trial: 36704479
Drug: Yiqi Fumai
RxNorm normalized name: Aspergillus fumigatus allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Fumai lyophilized injection (YQFM)
Trial: 36704634
Drug: Control (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (only pharmacological therapy)
Trial: 36704737
Drug: PSYCHOPATHY.COMP program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSYCHOPATHY.COMP program (20-session individual intervention based on Compassion Focused Therapy)
Trial: 36704757
Drug: My Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: My Sleep Our Sleep (MSOS) intervention delivered weekly for 4 weeks
Trial: 36704795
Drug: Micronutrient-containing supplement
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-containing supplement including zinc, taken preconception and throughout pregnancy until birth.
Trial: 36705433
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment for comorbid posttraumatic stress and substance use disorders
Trial: 36705474
Drug: Intralesional PPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional PPD immunotherapy for the largest wart (Group A)
Trial: 36705526
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg every 3 weeks with enzalutamide 160 mg once daily and ADT
Trial: 36705526
Drug: placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo every 3 weeks with enzalutamide 160 mg once daily and ADT
Trial: 36705566
Drug: 145 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 145 mg/day of nanocrystallized fenofibrate
Trial: 36705924
Drug: SGM-101 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGM-101 (10 mg) infused up to 5 days before index operation.
Trial: 36705941
Drug: Sodium phenylbutyrate-taurursodiol
RxNorm normalized name: sodium phenylbutyrate-taurursodiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium phenylbutyrate-taurursodiol (PB-TURSO), a combination of 3 g of PB and 1 g of TURSO given twice daily.
Trial: 36705941
Drug: AMX0035 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX0035 (a sachet containing a fixed co-formulation of 3 g of PB and 1 g of TURSO given twice daily).
Trial: 36706645
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg twice daily during NACT
Trial: 36706655
Drug: Niraparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (300 mg/day fixed starting dose or individualized starting dose according to baseline body weight and platelet count)
Trial: 36706655
Drug: Individualized starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individualized starting dose (ISD) of niraparib
Trial: 36706655
Drug: Fixed starting
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed starting dose of niraparib
Trial: 36706675
Drug: In-person counselling
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person counselling (45-70 minutes, two sessions over three months) with interim monthly booster phone calls (live call arm)
Trial: 36706675
Drug: In-person counselling
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person counselling (45-70 minutes, two sessions over three months) with twice-weekly automated booster sessions (technology arm)
Trial: 36706754
Drug: Lentivirus-based gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentivirus-based gene therapy
Trial: 36706754
Drug: Targeted treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatments to protect HSCs
Trial: 36706958
Drug: Dose-escalated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalated radiotherapy to the whole primary tumour
Trial: 36706958
Drug: Dose-escalated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalated radiotherapy to a PET-defined subvolume
Trial: 36707080
Drug: Intensive antiplatelet
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Trial: 36707080
Drug: Intensive antiplatelet
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90)
Trial: 36707080
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Trial: 36707080
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy plus delayed intensive statin therapy
Trial: 36707808
Drug: Trifluridine/tipiracil (FTD/TPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (FTD/TPI) 35 mg/m²
Trial: 36707841
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 20% hypertonic saline solution (HSS) to maintain blood sodium level between 150 and 155 mmol/L for at least 48 hours.
Trial: 36708539
Drug: CCB use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB use in single antihypertensive agent
Trial: 36708539
Drug: CCB use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB use in > 1 antihypertensive agent
Trial: 36708650
Drug: Propolis (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (4 capsules of 100 mg/day for two months)
Trial: 36708650
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules of 100 mg/day for two months)
Trial: 36708732
Drug: High-dose protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose protein (≥2·2 g/kg per day)
Trial: 36708732
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose protein (≤1·2 g/kg per day)
Trial: 36708734
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate treatment over 2 years
Trial: 36708734
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment over 2 years
Trial: 36708738
Drug: CIS43LS 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS 1 mg/kg intravenously
Trial: 36708738
Drug: CIS43LS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS 5 mg/kg intravenously
Trial: 36708738
Drug: CIS43LS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS 10 mg/kg intravenously
Trial: 36708738
Drug: CIS43LS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS 5 mg/kg subcutaneously
Trial: 36708738
Drug: CIS43LS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS 10 mg/kg subcutaneously
Trial: 36708966
Drug: Multimedia tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia tablet
Trial: 36709074
Drug: cAd3-Marburg vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cAd3-Marburg vaccine (1×10^11 viral particles)
Trial: 37517413
Drug: Momelotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib (200 mg orally once per day)
Trial: 37517413
Drug: Danazol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (300 mg orally twice per day)
Trial: 36709275
Drug: All BI
RxNorm normalized name: BISMUTH SUBSALICYLATE 262 mg ORAL TABLET, CHEWABLE [rexall bismuth]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All BI 425809 treatment groups
Trial: 36710399
Drug: roxadustat 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxadustat 2.0 mg/kg
Trial: 36710399
Drug: roxadustat 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxadustat 2.5 mg/kg
Trial: 36711070
Drug: Dermocosmetic (DC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermocosmetic (DC) applied twice daily for 28 days
Trial: 36711127
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EPs (P3 and P10) and image-derived information
Trial: 36711671
Drug: Friendship Bench
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friendship Bench intervention (six weekly individual counselling sessions of problem-solving therapy)
Trial: 36711869
Drug: Mifepristone (glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (glucocorticoid receptor antagonist)
Trial: 36711869
Drug: Yohimbine (α2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (α2 receptor antagonist)
Trial: 38491376
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention (EBI; protocol-based hypertension treatment)
Trial: 36712824
Drug: Surgical debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical debridement and hyperbaric oxygen therapy
Trial: 36712888
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone
Trial: 36712888
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with triple antiemetic therapy (fosaprepitant, ondansetron, and dexamethasone)
Trial: 36713413
Drug: AZD1222 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1222 vaccine
Trial: 36713761
Drug: Rivaroxaban plus
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban plus antiplatelet therapy (combination therapy)
Trial: 36714040
Drug: Intraoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative ketamine administration (group K)
Trial: 36714040
Drug: No ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ketamine administration (group NK)
Trial: 36714197
Drug: Social app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Social app care group (warfarin therapy guided by experienced clinicians via a social app)
Trial: 36714197
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care group (warfarin therapy managed through traditional in-office visits)
Trial: 36715014
Drug: hTERT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hTERT vaccine UV1 combined with androgen deprivation therapy (ADT) and radiotherapy
Trial: 36715152
Drug: Prasugrel dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel dose de-escalation (5 mg daily)
Trial: 36715152
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (prasugrel 10 mg daily)
Trial: 36715655
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antidepressants and fear-avoidance rehabilitation
Trial: 36715712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of crush injury, PT, and NEU
Trial: 36716031
Drug: SER-109 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-109 (4 capsules once daily for 3 days)
Trial: 36716310
Drug: Evidence-based practices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based practices including subglottic suctioning, daily assessment for spontaneous awakening trial (SAT), spontaneous breathing trial (SBT), head of bed elevation, and avoidance of neuromuscular blockers unless otherwise indicated.
Trial: 36716382
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneously plus SoC
Trial: 36716759
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable (LAI) antipsychotics (paliperidone and aripiprazole)
Trial: 36716759
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (paliperidone and aripiprazole)
Trial: 36716759
Drug: Combined LAI
RxNorm normalized name: laidlomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined LAI treatment
Trial: 36716759
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral treatment
Trial: 36716759
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (LAI vs Oral)
Trial: 36716761
Drug: Emicizumab 3
RxNorm normalized name: Emicizumab 30 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 3 mg/kg subcutaneously once weekly for 4 weeks, followed by maintenance doses of 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks.
Trial: 36716780
Drug: Sex hormones
RxNorm normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormones (estrone, estradiol, testosterone, dehydroepiandrosterone)
Trial: 36716780
Drug: Null findings
RxNorm normalized name: Nullo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Null findings for sex hormones
Trial: 36716960
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions with concurrent i.v. cisplatin (75mg/m2)
Trial: 36716960
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic radiotherapy of 60 Gy in 40 fractions with concurrent i.v. cisplatin (75mg/m2)
Trial: 36717148
Drug: Active sTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active sTMS treatment for 6 weeks
Trial: 36717148
Drug: Sham sTMS
RxNorm normalized name: STM-217
DrugBank: STM-217 (DB17358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham sTMS treatment for 6 weeks
Trial: 36717148
Drug: At-home sTMS
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home sTMS administration
Trial: 36717150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipilimumab and nivolumab with SBRT (24 Gray in three fractions)
Trial: 36717150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipilimumab and nivolumab without SBRT
Trial: 36717150
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipilimumab and nivolumab with SBRT
Trial: 36717385
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with low-dose B vitamins plus betaine (400 μg folic acid, 8 mg vitamin B) for 12 weeks
Trial: 36717539
Drug: Meplazumab 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meplazumab 0.12 mg/kg
Trial: 36717539
Drug: Meplazumab 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meplazumab 0.2 mg/kg
Trial: 36717539
Drug: Meplazumab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meplazumab 0.3 mg/kg
Trial: 36717556
Drug: Injectable intramuscular
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Trial: 36718142
Drug: Avelumab 800
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 800 mg (days 1 and 8) + Cetuximab 250 mg/m2
Trial: 36718142
Drug: Avelumab +
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab + Cetuximab + Chemotherapy
Trial: 36718400
Drug: Hypnotic Analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic Analgesia (HAS)